ErbB2/Her2 [p Tyr1248] Antibody

Immunohistochemistry-Paraffin: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960]

Immunohistochemistry-Paraffin: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Human lung carcinoma tissue.

Immunohistochemistry-Paraffin: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] -

Immunohistochemistry-Paraffin: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Immunohistochemical analysis of paraffin-embedded human breast carcinoma, using NB100-81960. The picture on the right is blocked with the phospho peptide.

Western Blot: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] -

Western Blot: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Western blot analysis of lysates from HepG2 cells treated with PMA 125ng/ml 30', using NB100-81960. The lane on the right is blocked with the phospho peptide.

Western Blot: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] -

Western Blot: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Western Blot analysis of 293 cells using NB100-81960 diluted at 1: 1000

Western Blot: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] -

Western Blot: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Western blot analysis of lysates from HepG2 cells treated with PMA 125ng/ml 30', using NB100-81960. The lane on the right is blocked with the phospho peptide.

Immunocytochemistry/ Immunofluorescence: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] -

Immunocytochemistry/ Immunofluorescence: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Mutant ERBB2 cooperates with loss of p53 & leads to papillary GBC in recipient mice. (A) Top: Schematic of human ERBB2, indicating the location of two point mutants (S310F & V777L). Bottom: retroviral vector used to transduce organoids, that had been treated with an sgp53-containing plasmid (px459) to induce loss of p53. (B) Immunofluorescence for ERBB2 (top) & phospho-ERBB2 (bottom) on organoids harboring the indicated genetic alterations. (C) Tumor volumes 36 days after s.c. implantation of the respective organoids into recipient mice. All mice transplanted with sgp53;ERBB2S310F- & sgp53;ERBB2V777L organoids exhibited tumor development, whereas sgp53;empty vector- & sgp53;ERBB2wildtype organoids did not give rise to tumors over a four-month observation period. There was no significant difference in the tumor burden of mice transplanted with sgp53;ERBB2S310F- & sgp53;ERBB2V777L organoids (p = 0.999). (D) Mice transplanted with sgp53;ERBB2S310F- & sgp53;ERBB2V777L organoids reached endpoint criteria with a median survival of 79.5 days & 58.5 days, respectively. (E) H&E & IHC for CK19 & EGFP on tumors generated with sgp53;ERBB2S310- & sgp53;ERBB2V777L organoids. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31795490), licensed under a CC-BY license. Not internally tested by Novus Biologicals.